Ovid Therapeutics (OVID) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

OVID Ovid Therapeutics

Watchlist

0.970
-0.028-2.80%

Close Dec 27 16:00 ET

0.950
-0.020-2.08%

Post 18:30 ET

68.89MMarket Cap-2.11P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Ovid Therapeutics' OV329: Promising Safety and Efficacy Lead to Buy Rating
TipRanksDec 10 07:05 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Ovid Therapeutics (OVID)
TipRanksDec 9 08:20 ET · Ratings
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $3
Moomoo NewsDec 5 11:35 ET · Ratings
Ovid Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow JonesDec 4 06:59 ET · Ratings
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4
Moomoo NewsNov 14 09:33 ET · Ratings
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating
Moomoo NewsNov 14 08:31 ET · Ratings

Comments

MARKET-TEST-DUMMY

Jul 20 09:27

👀

$Ovid Therapeutics (OVID.US)$

70205719

Jul 12 16:19

$Ovid Therapeutics (OVID.US)$ break 1.17 next week, then fill in the gap sooner.

TraderKen26

Jul 1 19:11

$Ovid Therapeutics (OVID.US)$ why the super dump?

Jaguar8

Jul 1 13:07

NEWS

$Ovid Therapeutics (OVID.US)$
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
Ovid Therapeutics and Graviton Bioscience announced positive Phase 1 trial results for their OV888/GV101 capsule, a potential first-in-class therapy for cerebral cavernous malformations (CCM). The trial met its primary objective by demonstrating a favorable safety and to...

Jaguar8

Jun 17 06:40

NEWS

$Ovid Therapeutics (OVID.US)$
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
Ovid Therapeutics reported on Takeda's Phase 3 study results for soticlestat, a treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The Skyline study in DS narrowly missed its primary endpoint but showed significant effects in secondary endpoints with p-values ≤ 0.008. The Skyway study in LGS missed its primary endpoint. Soticlestat had a favorabl...

Heat List

Overall

No Data